Literature DB >> 33236424

Telemedicine for allergic patients during COVID-19.

Stefano Pattini1, Velia Malizia2, Alessandro Travaglini3, Maria Antonia Brighetti3, Auro Della Giustina4, Ifigenia Sfika5, Alessandro Di Menno Di Bucchianico6, Salvatore Tripodi7.   

Abstract

In the last few years, we have witnessed an important development in the medical field of both Mobile Health, such as the use of mobile communication devices, and other telemedicine tools in general, in order to support the surveillance of diseases from the moment of the first diagnosis to the therapeutic follow-up. Long before COVID-19, some authors had analyzed various possible evidence-based scenarios and had indicated how the use of telemedicine could prove to be extremely useful in epidemic situations, especially for the management of chronic patients, such as immune-allergic ones, who are notoriously in greater need of regular follow-up; however, as expected, the advent of the COVID-19 pandemic has amplified the differences between various countries, from the point of view of the propensity to use technological solutions in the health sector. The hope is that one positive outcome of the ongoing pandemic is that it will lead to an acceleration, by all the stakeholders involved, of the process of modernization of health care.
© 2020 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID-19; apps; contact tracing; immune-allergic patients; telemedicine

Mesh:

Year:  2020        PMID: 33236424     DOI: 10.1111/pai.13346

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  2 in total

Review 1.  Digital tools in allergy and respiratory care.

Authors:  Elisabeth Verhoeven; Philip Rouadi; Eliane Abou Jaoude; Mohamed Abouzakouk; Ignacio Ansotegui; Mona Al-Ahmad; Maryam Ali Al-Nesf; Cecilio Azar; Sami Bahna; Lyda Cuervo-Pardo; Zuzana Diamant; Habib Douagui; R Maximiliano Gómez; Sandra González Díaz; Joseph K Han; Samar Idriss; Carla Irani; Marilyn Karam; Ludger Klimek; Talal Nsouli; Glenis Scadding; Brent Senior; Pete Smith; Anahí Yáñez; Fares Zaitoun; Peter W Hellings
Journal:  World Allergy Organ J       Date:  2022-06-23       Impact factor: 5.516

2.  Comments on metabolomics in asthma and atopic dermatitis, and patient care during the COVID-19 pandemic.

Authors:  Philippe Eigenmann
Journal:  Pediatr Allergy Immunol       Date:  2021-11       Impact factor: 6.377

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.